Taking Wegovy and Orlistat Together: Is It Safe?

Most clinicians would not recommend taking Wegovy and orlistat at the same time. There is no published clinical trial testing this combination, and both drugs carry overlapping gastrointestinal side effects that are likely to compound. The interaction is flagged in some drug interaction databases as moderate, though the BNF does not formally list a specific interaction entry. The practical guidance from prescribers is clear: choose one or switch between them, rather than stack them.

How each drug works#

Wegovy contains semaglutide, a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness to the brain, reduces appetite, and slows how quickly food leaves your stomach. In the STEP 1 trial, participants on semaglutide 2.4mg lost an average of 14.9% of their body weight over 68 weeks. Longer follow-up data from the STEP 5 trial, looking at semaglutide use up to 104 weeks, showed continued weight reduction in a similar range.

Orlistat works entirely differently. It blocks an enzyme called lipase in the gut, stopping roughly one-third of the fat you eat from being absorbed. That unabsorbed fat passes through your bowel instead. Orlistat comes as Xenical (120mg, prescription only) or Alli (60mg, available over the counter at UK pharmacies without a prescription).

Because the mechanisms differ, combining them might seem logical. In practice, the interaction picture is more complicated.

What happens when you take both#

Two pharmacokinetic concerns arise when these drugs are used together.

First, semaglutide significantly slows gastric emptying. Food (and any fat within it) moves through the gut more slowly. Orlistat works by sitting in the gut and blocking lipase as fat passes by. If transit time is slowed by semaglutide, the fat-orlistat contact time changes, and this could reduce orlistat's effectiveness. No published study has directly measured this effect, but the mechanism is pharmacologically plausible.

Second, semaglutide is an injectable drug, so it bypasses gut absorption entirely. The interaction concern around semaglutide absorption is less relevant for the injection. However, if you are taking Wegovy Tablets (oral semaglutide), the picture is different. Oral semaglutide is a peptide taken with a specialised absorption enhancer and requires specific conditions: an empty stomach, a small amount of plain water, and remaining upright for at least 30 minutes afterwards. Orlistat alters gut motility and fat absorption dynamics. Taking both oral semaglutide and orlistat together could plausibly reduce how much semaglutide reaches your bloodstream. This is a more direct concern than with the injection, and a stronger reason to avoid the combination if you are using Wegovy Tablets specifically.

The GI side effect problem#

Even setting aside the absorption question, the gastrointestinal side effect profiles of these two drugs overlap badly.

The 44% nausea figure comes from cumulative incidence across the STEP 1 trial period, not a rate you experience every day. It does reduce as your body adjusts. But early in treatment, when nausea is most common, adding orlistat's typical oily stools and frequent bowel movements creates a combination that is genuinely difficult to tolerate.

Fat-soluble vitamin depletion: a compounded risk#

Orlistat reduces absorption of fat-soluble vitamins: A, D, E and K. This is why prescribers recommend a multivitamin containing these vitamins when using orlistat, taken at least two hours away from the orlistat dose or at bedtime.

Wegovy suppresses appetite significantly. Many people on semaglutide eat considerably less, and some eat a narrower range of foods. Combine reduced food intake with impaired fat-soluble vitamin absorption, and the risk of micronutrient deficiency rises. This is worth discussing with your prescriber, particularly if you have been on orlistat for some time before starting Wegovy, or if your diet has narrowed on semaglutide.

The UK prescribing pathway#

For most people in England, the question of combining these drugs does not arise in a planned way. NICE NG246 (2023), which sets out the obesity treatment pathway, recommends that pharmacotherapy be considered as part of a structured weight management programme. It supports escalating to more effective treatments, but does not endorse simultaneous use of multiple weight loss drugs.

On the NHS, orlistat is often the first medication offered. Wegovy on the NHS is available through specialist weight management services, not typically as a first-line GP prescription. So the real-world scenario is usually a patient who has been taking orlistat (on prescription or OTC as Alli) who then starts Wegovy privately, without the two prescribers necessarily knowing about each other.

If you buy Alli from a pharmacy without a prescription and also receive a Wegovy prescription, there may be no single clinician overseeing both. This is the clinical governance gap worth being aware of. A GPhC-registered pharmacy dispensing either drug has a duty of care to ask about other medications you are taking.

Switching from orlistat to Wegovy#

Switching is the more sensible option for most people. There is no formal washout period required before stopping orlistat and starting Wegovy. Orlistat works locally in the gut and does not accumulate systemically, so it clears quickly once stopped. In practice, most prescribers would stop orlistat on the day you start Wegovy, or shortly before.

Wegovy is dosed gradually over 16 weeks, starting at 0.25mg weekly and stepping up every four weeks. The maintenance dose of 2.4mg is reached at week 17. This slow escalation is designed to reduce the nausea and GI side effects that are most common at the start of treatment. You can read more about the dosing schedule in the Wegovy doses guide.

If you are considering switching or want to explore whether Wegovy or another option is right for you, the Totiva weight loss service page covers the treatments currently available, including Wegovy tablets, the Wegovy injection and Mounjaro.

Red flags to act on quickly#

If you are taking either drug and experience any of the following, seek medical attention promptly:

• Severe abdominal pain, especially pain that spreads to your back. This can indicate pancreatitis, a rare but serious risk with GLP-1 medicines.
• Yellowing of your skin or eyes, which may suggest a liver problem.
• Prolonged vomiting or diarrhoea leading to signs of dehydration: dark urine, dizziness, or not passing urine.
• Any unexpected or severe reaction you are not sure about.

You can report unexpected side effects from either drug via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. This is especially relevant if you are taking both drugs at the same time, as combination effects are not well studied and reporting helps build the evidence base.

If you are currently on orlistat and want to explore your next steps, a clinician can review your medication history and advise on the right pathway. You can start a free weight loss consultation at Totiva without needing a subscription, and you only pay if treatment is appropriate and approved for you.